 |
 |
 |
 |
Bringing Together Care and Research for Better, Safer, and More Effective Treatments
HIV research studies are essential to provide critical information to help people live longer, healthier, and more comfortable lives.
Our mission has been to develop and provide the highest-quality treatment and care for people living with HIV through research.
We are part of the AIDS Clinical Trials Group (ACTG) of the National Institutes of Health (NIH). The ACTG, the largest HIV clinical-trials organization, plays a major role in defining the standards of care for treatment of HIV infection and opportunistic diseases related to HIV/AIDS around the world.
Treatment Experienced
Hepatitis
Treatment Experienced
The following studies are for people who are treatment experienced, meaning that they are currently on medications or have taken medications in the past for HIV. Each study has a unique approach: Which are the best medications to treat with? When is the best time to change medications? How do we know when to change medications?
| Study Number | POEM |
|---|---|
| Study Name | This is a study of the long-term follow-up of participants starting Maraviroc containing regimen. |
| Description | Maraviroc, in combination with other antiretroviral medicinal products, is indicated for treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable. |
| Who Is Eligible | Males and non-pregnant non-breastfeeding females, age 18 or older Eligible to start a Maraviroc containing regimen |
| For More Information | Call (212) 305-7897 or e-mail HIV_Studies@columbia.edu |
| Study Number | MRK055 |
| Study Name | A phase III open-label single arm study to evaluate the safety, tolerability, and efficacy of MK-0518/Raltegravir in a diverse cohort or HIV-Infected patients. |
| Description | This is a study of long term safety and tolerability f/u of minority and/or women volunteers starting a Raltegravir containing regimen. |
| Who Is Eligible | Men and women age 21 or older Starting a Raltegravir containing regimen |
| For More Information | Call (212) 305-7897 or e-mail HIV_Studies@columbia.edu |
| Study Number | A5240 |
| Study Name | A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV–1 infected Females. |
| Description | This study will assess the immunogenicity, safety, and tolerability of the quadrivalent human papillomavirus (HPV) recombinant vaccine (GARDASIL) directed against types 6, 11, 16, 18. All participants will be vaccinated by intramuscular injection at day 0 and weeks 8 and 24, and followed for a total of 72 weeks. |
| Who Is Eligible |
|
| For More Information | Call (212) 305-7897 or e-mail |
| Study Number | A5241 |
| Study Name | The Optimized Treatment that Includes or Omits NRTIs (OPTIONS) Trial: A Randomized Strategy Study for HIV-1-infected Treatment-Experienced Subjects Using the cPSS to Select an Effective Regimen |
| Description | This is a strategy study for triple-class antiretroviral-experienced or resistant HIV-1 infected subjects that will evaluate the benefit of adding nucleoside reverse transcriptase inhibitors (NRTIs) to a new antiretroviral regimen. A continuous phenotype susceptibility score (cPSS) will be calculated based upon a real-time HIV-1 phenotype/genotype and co-receptor tropism assays to help in selecting a potent salvage regimen. Subjects for whom a study regimen with a cPSS>2.0 can be identified will be randomized to receive a new regimen with or without NRTIs. The study team will recommend options for a new regimen, which may include raltegravir, maraviroc, enfuvirtide, darunavir, tipranavir, or etravirine. The site investigator and subject will choose from the recommended options. |
| Who Is Eligible |
|
| For More Information | Call (212) 305-7897 or e-mail |
Hepatitis
People with HIV may also be infected with other viruses, such as Hepatitis B or Hepatitis C. There are trials for the treatment of co-infected patients.
